Born to survive: how cancer cells resist CAR T cell therapy

Abstract

Abstract Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant cancer cells. Here, we review the intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to circumvent them.

Keywords

• Immunotherapy
• Lymphoma
• Leukemia
• Myeloma
• Therapy